Literature DB >> 16239436

Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation.

Mark Cook1, David Briggs, Charles Craddock, Premini Mahendra, Donald Milligan, Christopher Fegan, Philip Darbyshire, Sarah Lawson, Elizabeth Boxall, Paul Moss.   

Abstract

Reactivation of cytomegalovirus (CMV) is a common complication following allogeneic stem cell transplantation. Genetic determinants in the host and donor that may influence the rate of reactivation are currently unknown. Viral replication is controlled by T cells and natural killer (NK) cells and these share expression of killer immunoglobulin-like receptors (KIRs). We analyzed whether activatory KIRs carried by the donor influenced the subsequent rate of CMV reactivation in the patient. In transplantations involving siblings where both donor and recipient were CMV seropositive, donors with more than one activating KIR gene were associated with a 65% reduction in CMV reactivation. Multivariate analysis confirmed a significantly reduced risk of CMV reactivation in sibling transplantations where the donor had more than one activating KIR. Reduced-intensity transplantation and graft-versus-host disease grade 2 or higher were associated with an increased risk of CMV reactivation. This observation indicates that activating KIRs play an important role in the cellular control of CMV reactivation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16239436     DOI: 10.1182/blood-2005-03-1039

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  61 in total

Review 1.  The tortoise and the hare: slowly evolving T-cell responses take hastily evolving KIR.

Authors:  Jeroen van Bergen; Frits Koning
Journal:  Immunology       Date:  2010-08-17       Impact factor: 7.397

Review 2.  How we treat cytomegalovirus in hematopoietic cell transplant recipients.

Authors:  Michael Boeckh; Per Ljungman
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

Review 3.  Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease.

Authors:  James O J Davies; Kate Stringaris; A John Barrett; Katayoun Rezvani
Journal:  Cytotherapy       Date:  2014-05-20       Impact factor: 5.414

4.  High KIR diversity in Amerindians is maintained using few gene-content haplotypes.

Authors:  Ketevan Gendzekhadze; Paul J Norman; Laurent Abi-Rached; Zulay Layrisse; Peter Parham
Journal:  Immunogenetics       Date:  2006-05-05       Impact factor: 2.846

Review 5.  Targeting natural killer cells and natural killer T cells in cancer.

Authors:  Eric Vivier; Sophie Ugolini; Didier Blaise; Christian Chabannon; Laurent Brossay
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

6.  NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs.

Authors:  Vivien Béziat; Lisa L Liu; Jenny-Ann Malmberg; Martin A Ivarsson; Ebba Sohlberg; Andreas T Björklund; Christelle Retière; Eva Sverremark-Ekström; James Traherne; Per Ljungman; Marie Schaffer; David A Price; John Trowsdale; Jakob Michaëlsson; Hans-Gustaf Ljunggren; Karl-Johan Malmberg
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

Review 7.  Cytotoxic potential of decidual NK cells and CD8+ T cells awakened by infections.

Authors:  Ângela C Crespo; Anita van der Zwan; João Ramalho-Santos; Jack L Strominger; Tamara Tilburgs
Journal:  J Reprod Immunol       Date:  2016-08-02       Impact factor: 4.054

8.  Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.

Authors:  Heather J Symons; M Sue Leffell; Nancy D Rossiter; Marianna Zahurak; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-02       Impact factor: 5.742

Review 9.  Natural killer cells: tolerance to self and innate immunity to viral infection and malignancy.

Authors:  Wayne M Yokoyama; Marcus Altfeld; Katharine C Hsu
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-14       Impact factor: 5.742

10.  Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation.

Authors:  Jill C Beck; John E Wagner; Todd E DeFor; Claudio G Brunstein; Mark R Schleiss; Jo-Anne Young; Daniel H Weisdorf; Sarah Cooley; Jeffrey S Miller; Michael R Verneris
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-26       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.